Singh Naveena, Gilks C Blake, Hirshowitz Lynn, Wilkinson Nafisa, McCluggage W Glenn
Department of Cellular Pathology (N.S.), Barts Health NHS Trust, LondonDepartment of Cellular Pathology (L.H.), Birmingham Women's NHS Trust, BirminghamDepartment of Pathology (N.W.), St James's Hospital, LeedsDepartment of Pathology (W.G.M), Belfast Health and Social Care Trust, Belfast, UKDepartment of Anatomic Pathology (C.B.G.), Vancouver General Hospital, and University of British Columbia, Vancouver, BC, Canada.
Int J Gynecol Pathol. 2016 May;35(3):230-7. doi: 10.1097/PGP.0000000000000270.
There is currently sufficient evidence that nonuterine high-grade serous carcinoma (HGSC) originates in the fallopian tube in the majority of cases, but this is not uniformly reflected in our diagnostic terminology. This is because there remains wide variation in awareness and acceptance of this evidence, which conflicts with traditional views on origin. Accurate disease classification is fundamental to routine clinical practice and research, particularly at a time when exciting new approaches to therapy, early detection, and prevention are appearing on the horizon. We feel the time has come to minimize individual and institutional variations in practice, and agree on an evidence-based approach to uniform terminology and primary site assignment. In this paper we put forward a proposal for a unified approach based on published research evidence and discuss the reasons why it is vital to agree on a uniform protocol. We propose the term "Tubo-ovarian HGSC" in preference to "pelvic" or "Müllerian," as it accurately reflects the origin of this disease in the vast majority of cases, and is unambiguous, distinguishing it clearly from uterine serous carcinoma and ovarian low-grade serous carcinomas. A detailed protocol for primary site assignment is presented for different scenarios, which is easy to follow and has been developed with a view to promoting a uniform approach worldwide.
目前有充分证据表明,大多数非子宫高级别浆液性癌(HGSC)起源于输卵管,但这在我们的诊断术语中并未得到一致体现。这是因为对这一证据的认识和接受程度仍存在很大差异,这与关于起源的传统观点相冲突。准确的疾病分类对于常规临床实践和研究至关重要,尤其是在令人兴奋的新治疗方法、早期检测和预防方法即将出现之际。我们认为现在是时候尽量减少实践中的个体和机构差异,并就基于证据的统一术语和原发部位指定方法达成一致了。在本文中,我们基于已发表的研究证据提出了一种统一方法的建议,并讨论了就统一方案达成一致至关重要的原因。我们建议使用“输卵管卵巢HGSC”这一术语,而不是“盆腔”或“苗勒管”,因为它在绝大多数情况下准确反映了这种疾病的起源,并且明确无误,将其与子宫浆液性癌和卵巢低级别浆液性癌清楚地区分开来。针对不同情况给出了详细的原发部位指定方案,该方案易于遵循,并且是为了在全球范围内推广统一方法而制定的。